-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

Benzinga·10/08/2026 12:24:14
语音播报
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $115 to $130.